Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients

Journal of Psychiatric Research

Volumn 47, Issue 12, 2013, Pages 1843-1848

  Hori, Hikaru ^a   Yoshimura, Reiji ^a   Katsuki, Asuka ^a   Sugita, Atsuko Ikenouchi ^a   Atake, Kiyokazu ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

BACS J; Cognitive function; LASMI; Monopharmacy; PANSS; Polypharmacy; Schizophrenia; Social function; Switching

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; EDUCATION; EXECUTIVE FUNCTION; FEMALE; HANDEDNESS; HUMAN; INTELLIGENCE QUOTIENT; INTELLIGENCE TEST; LEARNING; MALE; MENTAL PATIENT; MONOTHERAPY; MOTOR PERFORMANCE; POLYPHARMACY; PRIORITY JOURNAL; PROCESSING SPEED; SCHIZOPHRENIA; SKILL; SMOKING; SOCIAL BEHAVIOR; VERBAL MEMORY; WORKING MEMORY;

BACS-J; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA, JAPANESE-LANGUAGE VERSION; COGNITIVE FUNCTION; LASMI; LIFE ASSESSMENT SCALE FOR THE MENTALLY III; MONOPHARMACY; PANSS; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SOCIAL FUNCTION; SWITCHING;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHRONIC DISEASE; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; INTELLIGENCE TESTS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886099726     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.08.024     Document Type: Article

References (40)

1. American Psychiatric Association Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 2004, 161:1-56. 2nd edition.
2. Aleman A., Agrawal N., Morgan K.D., David A.S. Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry 2006, 189:204-212.
3. Aston-Jones G., Rajkowski J., Kubiak P., Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. JNeurosci 1994, 14(7):4467-4480.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36(1):71-93. Schizophrenia Patient Outcomes Research Team (PORT).
5. Centorrino F., Eakin M., Bahk W.M., Kelleher J.P., Goren J., Salvatore P., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002, 159(11):1932-1935.
6. Choi J.W., Bum S.J., Kim J.W. Dysfunction of the left dorsolateral prefrontal cortex is primarily responsible for impaired attentional processing in schizophrenia. Psychiatry Investig 2008, 5(1):52-59.
7. Demily C., Franck N. Cognitive remediation: a promising tool for the treatment of schizophrenia. Expert Rev Neurother 2008, 8(7):1029-1036.
8. Essock S.M., Schooler N.R., Stroup T.S., McEvoy J.P., Rojas I., Jackson C., et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011, 168(7):702-708.
9. Elie D., Poirier M., Chianetta J., Durand M., Gregoire C., Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy; a study with the BACS in patients with schizophrenia and schizoaffective disorder. JPsychopharmacol 2010, 24(7):1037-1044.
10. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. JClin Psychiatry 2004, 65(10):1377-1388.
11. Green M.F., Barnes T.R., Danion J.M., Gallhofer B., Meltzer H.Y., Pantelis C. The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. Schizophr Res 2005, 74(2-3):253-261.
12. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., et al. Patient outcomes in shizoophrenia II: the impact of cognition. Eur Psychiatry 2005, 20(5-6):395-402.
13. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokine, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007, 22(1):21-27.
14. Hori H., Yoshimura R., Katsuki A., Hayashi K., Ikenouchi-Sugita A., Umene-Nakano W., et al. Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. Int J Psychiatry Clin Pract 2012, 16(2):138-142.
15. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86(1-3):138-146.
16. Hori H., Noguchi H., Hashimoto R., Okabe S., Saitoh O., Kunugi H. IQ decline and memory impairment in Japanese patients with chronic schizophrenia. Psychiatry Res 2008, 158(2):251-255.
17. Inadomi H., Tanaka G., Watanabe S., Nagatomi Y., Mitarai K., Ohsawa R., et al. Efficacy of 3-year psychiatric daycare treatment in patients with schizophrenia. Psychiatry Clin Neurosci 2005, 59(3):246-252.
18. Iwanami A., Yamashina M., Kazamatsuri H., Kamijima K. P300 and disability of daily life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23(3):423-430.
19. Iwasaki S., Miyauchi M., Oshima I., Murata N., Nonaka T., Kato H. The development of life assessment scale for the mentally ill: an assessment of their reliability. Seishin Igaku 1994, 36:1139-1151. [in Japanese].
20. Kakihara S., Yoshimura R., Shinkai K., Matsumoto C., Goto M., Kaji K., et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005, 20(2):71-78.
21. Kaneda Y., Sumiyoshi T., Keefe R., Ishimoto Y., Numata S., Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry and Clin Neurosci 2007, 61(6):602-609.
22. Kaneda Y., Sumiyoshi T., Nakagome K., Numata S., Tanaka T., Ueoka Y., et al. The brief assessment of cognition in schizophrenia Japanese version (BACS-J). Seishinigaku 2008, 50(9):913-917. [in Japanese].
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) manual. Schizophr Bull 1987, 13(2):261-276.
24. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The brief assessment of cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004, 68(2-3):283-297.
25. Matsuoka K., Kim Y., Hiro H., Miyamoto Y., Fujita K., Tanaka K. Development of Japanese adult reading test (JART) for predicting premorbid IQ in mild dementia. Clin Psychiatry 2002, 44:503-511. [in Japanese)].
26. McDonalds A.W., Cohen J.D., Stenger V.A., Carter C.S. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000, 288(5472):1835-1838.
27. Medalia A., Choi J. Cognitive remediation in schizophrenia. Neuropsychol Rev 2009, 19(3):353-364.
28. Midorikawa A., Hashimoto R., Noguchi H., Saitoh O., Kunugi H., Nakamura K. Impairment of motor dexterity in schizophrenia assessed by a novel finger movement test. Psychiatry Res 2008, 159(3):281-289.
29. Miller A.L., Craig C.S. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002, 28(1):105-109.
30. Miller A., Hall C.S., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. JClin Psychiatry 2004, 65(4):500-508.
31. Nakano W., Yang S.-Y., Fujii S. The characteristics of pharmacotherapy for inpatients with schizophrenia in Japan-results from the international survey of psychotic drug prescription pattern in East Asia. Jpn J Clin Pcychopharmacol 2010, 13:103-113.
32. National Collaborating Centre for Mental Health Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care 2009, NICE Clinical Guideline 1 National Institute for Health and Clinical Excellence.
33. Nelson H.E., Wilson J.R. National adult reading test (NART) 1991, Test manual, NFER=NELSON, Windsor. 2nd ed.
34. Sirvio J., MacDonald E. Central alpha1-adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol Ther 1999, 83(1):49-65.
35. Smith A., Nutt D. Noradrenaline and attention lapses. Nature 1996, 380:28.
36. Stahl S.M. Antipsychotic polypharmacy: squandering precious resources?. JClin Psychiatry 2002, 63:93-94.
37. Suzuki T., Uchida H., Takeuchi H., Nomura K., Tanabe A., Watanabe K., et al. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology 2005, 181(3):566-575.
38. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(5):1072-1077.
39. Yoshimura R., Ueda N., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010, 11(2):256-261.
40. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Katsuki A., Hayashi K., et al. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 2012, 27(1):33-38.